Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance

Publication type:
Journal article
Metadata:
Autoren
  • Felix Schmidt
  • Thomas Efferth
DOI
10.3390/ph9020033
eISSN
1424-8247
Ausgabe der Veröffentlichung
2
Zeitschrift
Pharmaceuticals
Sprache
en
Online publication date
2016
Paginierung
33 - 33
Status
Published online
Herausgeber
MDPI AG
Herausgeber URL
http://dx.doi.org/10.3390/ph9020033
Datum der Datenerfassung
2022
Titel
Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance
Ausgabe der Zeitschrift
9

Data source: Crossref

Other metadata sources:
Abstract
Tumor heterogeneity has been compared with Darwinian evolution and survival of the fittest. The evolutionary ecosystem of tumors consisting of heterogeneous tumor cell populations represents a considerable challenge to tumor therapy, since all genetically and phenotypically different subpopulations have to be efficiently killed by therapy. Otherwise, even small surviving subpopulations may cause repopulation and refractory tumors. Single-cell sequencing allows for a better understanding of the genomic principles of tumor heterogeneity and represents the basis for more successful tumor treatments. The isolation and sequencing of single tumor cells still represents a considerable technical challenge and consists of three major steps: (1) single cell isolation (e.g., by laser-capture microdissection), fluorescence-activated cell sorting, micromanipulation, whole genome amplification (e.g., with the help of Phi29 DNA polymerase), and transcriptome-wide next generation sequencing technologies (e.g., 454 pyrosequencing, Illumina sequencing, and other systems). Data demonstrating the feasibility of single-cell sequencing for monitoring the emergence of drug-resistant cell clones in patient samples are discussed herein. It is envisioned that single-cell sequencing will be a valuable asset to assist the design of regimens for personalized tumor therapies based on tumor subpopulation-specific genetic alterations in individual patients.
Addresses
  • Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany. felixschmidt.online@googlemail.com.
Autoren
DOI
10.3390/ph9020033
eISSN
1424-8247
Externe Identifier
  • PubMed Identifier: 27322289
  • PubMed Central ID: PMC4932551
Open access
true
ISSN
1424-8247
Ausgabe der Veröffentlichung
2
Zeitschrift
Pharmaceuticals (Basel, Switzerland)
Sprache
eng
Medium
Electronic
Online publication date
2016
Open access status
Open Access
Paginierung
E33
Datum der Veröffentlichung
2016
Status
Published
Publisher licence
CC BY
Datum der Datenerfassung
2016
Titel
Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance.
Sub types
  • review-article
  • Review
  • Journal Article
Ausgabe der Zeitschrift
9

Files

https://www.mdpi.com/1424-8247/9/2/33/pdf?version=1466073078 https://europepmc.org/articles/PMC4932551?pdf=render

Data source: Europe PubMed Central

Abstract
Tumor heterogeneity has been compared with Darwinian evolution and survival of the fittest. The evolutionary ecosystem of tumors consisting of heterogeneous tumor cell populations represents a considerable challenge to tumor therapy, since all genetically and phenotypically different subpopulations have to be efficiently killed by therapy. Otherwise, even small surviving subpopulations may cause repopulation and refractory tumors. Single-cell sequencing allows for a better understanding of the genomic principles of tumor heterogeneity and represents the basis for more successful tumor treatments. The isolation and sequencing of single tumor cells still represents a considerable technical challenge and consists of three major steps: (1) single cell isolation (e.g., by laser-capture microdissection), fluorescence-activated cell sorting, micromanipulation, whole genome amplification (e.g., with the help of Phi29 DNA polymerase), and transcriptome-wide next generation sequencing technologies (e.g., 454 pyrosequencing, Illumina sequencing, and other systems). Data demonstrating the feasibility of single-cell sequencing for monitoring the emergence of drug-resistant cell clones in patient samples are discussed herein. It is envisioned that single-cell sequencing will be a valuable asset to assist the design of regimens for personalized tumor therapies based on tumor subpopulation-specific genetic alterations in individual patients.
Date of acceptance
2016
Autoren
  • Felix Schmidt
  • Thomas Efferth
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/27322289
DOI
10.3390/ph9020033
Externe Identifier
  • PubMed Central ID: PMC4932551
ISSN
1424-8247
Ausgabe der Veröffentlichung
2
Zeitschrift
Pharmaceuticals (Basel)
Schlüsselwörter
  • RNA sequencing
  • cancer treatment
  • circulating tumor cells
  • flow cytometry
  • individualized therapy
  • intratumoral heterogeneity
  • laser-capture microdissection
  • micromanipulation
  • multi-region sequencing
  • next generation sequencing
  • precision medicine
  • single-cell sequencing
  • tumor ecosystems
  • whole genome amplification
  • xenograft tumor models
Sprache
eng
Country
Switzerland
PII
ph9020033
Datum der Veröffentlichung
2016
Status
Published online
Datum, an dem der Datensatz öffentlich gemacht wurde
2016
Titel
Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance.
Sub types
  • Journal Article
  • Review
Ausgabe der Zeitschrift
9

Data source: PubMed

Beziehungen:
Property of

Tools